Holen Sie sich die Stockscreener-App
1.235
2.48%
0.025
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
TScan Therapeutics Announces Q1 2026 Financial Results, Phase 3 TSC-101 Trial Launch, and Pipeline Updates - Minichart
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance UK
Is TScan Therapeutics (TCRX) stock worth taking a position in - Newser
TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting - Yahoo Finance
TCRX Financials: Income Statement, Balance Sheet & Cash Flow | Tscan Therapeutics, Inc. - Stock Titan
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics (NASDAQ: TCRX) seeks big boost in authorized shares at 2026 meeting - Stock Titan
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TCRX: TCR T cell therapy shows >50% relapse reduction in AML/MDS, pivotal trial starts mid-2024 - TradingView
TCRX: TCR T cell therapy halves relapse rates in AML/MDS, with pivotal trial and expansion planned - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts - MarketBeat
H.C. Wainwright reiterates Buy on Tscan stock, $7 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Tscan stock, $7 target - Investing.com
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm
TScan Therapeutics (NASDAQ: TCRX) seeks approval to double authorized shares to 600M - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3%Here's What Happened - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3% – Here’s What Happened - Defense World
Market Recap: Will TScan Therapeutics Inc stock benefit from M A2026 Technical Overview & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Will TScan Therapeutics (TCRX) Stock Recover Soon | Price at $1.06, Up 5.45%Most Watched Stocks - Newser
TCRX Stock Analysis: TScan Therapeutics Inc. Biotech at $1 Level Following Small Daily Dip - Newser
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
TScan Therapeutics announces resignation of vice president of finance - Investing.com UK
TScan Therapeutics announces resignation of vice president of finance By Investing.com - Investing.com Australia
TScan Therapeutics (TCRX) CFO adds principal accounting officer role after VP finance resignation - Stock Titan
TCRX Technical Analysis & Stock Price Forecast - Intellectia AI
TCRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Strong analyst sentiment on TScan Therapeutics (TCRX) amid ongoing momentum in cell therapy space - MSN
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance
Earnings Risk: Will TScan Therapeutics Inc stock benefit from M A2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug Catalysts: Will TScan Therapeutics Inc outperform its industry peersQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Retail Trends: What is the implied volatility of TScan Therapeutics Inc2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
How does TScan Therapeutics Inc score in quality rankings2026 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Risk Check: Will TScan Therapeutics Inc outperform its industry peersMarket Sentiment Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Geopolitics Watch: Is TScan Therapeutics Inc. stock risky to hold now2026 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TCRXTscan Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00 - Defense World
What are the risks of holding TScan Therapeutics Inc2025 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Stop Loss: What is the next catalyst for TScan Therapeutics Inc2025 Market WrapUp & Weekly Return Optimization Alerts - baoquankhu1.vn
HC Wainwright Issues Positive Outlook for TCRX Earnings - MarketBeat
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright - MarketBeat
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):